Drugmaker reports 35% Y/Y jump in third-quarter adjusted profit, rev up 18% Y/Y
** GLAX's profit growth driven by strong demand for its respiratory drugs and antibiotic Augmentin, while demand for its vaccines also boosted earnings
** GLAX's profit growth driven by strong demand for its respiratory drugs and antibiotic Augmentin, while demand for its vaccines also boosted earnings
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。